Revvity and Profluent have partnered to develop an advanced base editing toolkit combining Profluent’s AI-engineered enzymes with Revvity's Pin-Point platform. This collaboration enhances the precision and safety of gene editing therapies by enabling single-nucleotide modifications while minimizing off-target effects. The toolkit leverages Profluent’s OpenCRISPR nuclease as a Cas9 alternative and supports multiplexed edits crucial for complex therapeutic applications, reflecting the growing integration of AI in synthetic biology and gene therapy development.